Flipkart’s Super.money Bets on AI Agents to Outdo Bigger Rivals1h ago Datasette 1.0a39 and 0.65.4 security releases1h ago Anthropic caught scientists using Claude to further biological weapon research2h ago Oracle says AI will save it from the SaaSpocalypse, not bring it on2h ago Congress Is Suddenly Waking Up to the AI Doomsday Threat3h ago Don’t ask ChatGPT 'What should I do?' — this simple prompt helps you make better decisions yourself3h ago Extreme Networks’ Agent ONE Coworker moves AI networking from dashboards to answers3h ago Introducing ChatGPT for Financial Services3h ago Tesla unveils driverless Cybercab in Japan for 1st time3h ago The AI safety vibe shift4h ago Sam Altman met with top power utilities about securing the electrical grid. He offered one possible solution: OpenAI's cyber services.4h ago OpenAI Is Open to Slowing Cutting-Edge AI, CEO Sam Altman Tells Staff4h ago Tencent-Backed Chipmaker Enflame Jumps 188% in Shanghai Debut4h ago Salesforce introduces Enterprise AI Harness, AI Control Plane4h ago

Flipkart’s Super.money Bets on AI Agents to Outdo Bigger Rivals1h ago Datasette 1.0a39 and 0.65.4 security releases1h ago Anthropic caught scientists using Claude to further biological weapon research2h ago Oracle says AI will save it from the SaaSpocalypse, not bring it on2h ago Congress Is Suddenly Waking Up to the AI Doomsday Threat3h ago Don’t ask ChatGPT 'What should I do?' — this simple prompt helps you make better decisions yourself3h ago Extreme Networks’ Agent ONE Coworker moves AI networking from dashboards to answers3h ago Introducing ChatGPT for Financial Services3h ago Tesla unveils driverless Cybercab in Japan for 1st time3h ago The AI safety vibe shift4h ago Sam Altman met with top power utilities about securing the electrical grid. He offered one possible solution: OpenAI's cyber services.4h ago OpenAI Is Open to Slowing Cutting-Edge AI, CEO Sam Altman Tells Staff4h ago Tencent-Backed Chipmaker Enflame Jumps 188% in Shanghai Debut4h ago Salesforce introduces Enterprise AI Harness, AI Control Plane4h ago

Healthcare Machine Learning4 min reading time

Superluminal Medicines Raises $60M Series B to Advance Obesity Drug

Unite.AIPublished 8 days ago

Superluminal Medicines secured $60M in a Series B round led by BVF Partners to advance its selective MC4R agonist drug for rare genetic obesity into Phase 1 trials by end of 2026. The funding will also expand its GPCR-focused AI-driven drug discovery platform.

#biotechnology #bvf-partners #drug-discovery #mc4r #nvidia #ra-capital-management #superluminal-medicines

More in Healthcare

Google DeepMind Releases AlphaGenome Atlas Mapping 9 Billion Human DNA

Forbes9h ago

Healthcare3 min read

Mark Wahlberg is coming to TechCrunch Disrupt 2026, and he wants to talk about your work, not his

TechCrunch7h ago

UK Is Urged to Overhaul Regulation of AI-Medical Devices

Covered by 2 sources1d ago